Skip to main content
Top

05-06-2018 | Prostate cancer | Article

Statin use and time to progression in men on active surveillance for prostate cancer

Journal: Prostate Cancer and Prostatic Diseases

Authors: Viranda H. Jayalath, Madhur Nayan, Antonio Finelli, Maria Komisarenki, Narhari Timilshina, Girish S. Kulkarni, Neil E. Fleshner, Bimal Bhindi, Andrew Evans, Alexandre R. Zlotta, Robert J. Hamilton

Publisher: Nature Publishing Group UK

Abstract

Purpose

Recent evidence suggests that statins may improve prostate cancer outcomes; however, their role in active surveillance (AS) is poorly characterized. We aimed to evaluate the association between statin use at diagnosis and time to progression on AS.

Materials and Methods

Data were obtained from a prospectively maintained cohort of men undergoing AS between 1995 and 2016 at our institution. All men satisfied the low-risk criteria: Gleason score <7, <4 positive cores, <50% involvement of any core, and prostate-specific antigen level <10.0 ng/dL. Kaplan–Meier curves and multivariable Cox proportional hazards were used to assess statin exposure at diagnosis and at time to pathological progression (failing to meet the low-risk criteria at biopsy) and therapeutic progression (first of pathological progression or initiation of definitive therapy). Reclassification at confirmatory biopsy (first postdiagnostic biopsy) and progression beyond confirmatory biopsy were evaluated independently.

Results

Low-risk criteria were met by 797 men. Reclassification at the confirmatory biopsy occurred in 194 (24%) men, 51 (26%) of whom were statin users. Statin use was not associated with reclassification at confirmatory biopsy (odds ratio (OR): 1.24, 95% confidence interval (CI): 0.77–1.99). Among the remaining 603 men (median age: 63 years; follow-up: 60 months; 23% statin users), 149 (24%) had pathologic progression, while 200 (33%) had therapeutic progression. Statin exposure was not associated with pathological (multivariable hazard ratio (HR) 0.79, 95% CI: 0.51–1.23) or therapeutic (multivariable-HR 0.81, 95% CI: 0.55–1.19) progression beyond the confirmatory biopsy. Sensitivity analyses did not alter conclusions.

Conclusions

In our study, statin use at diagnosis was not significantly protective against pathological or therapeutic progression in men undergoing AS for localized, low-risk prostate cancer.
Literature
1.
Moyer VA, US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force precommendation statement. Ann Intern Med. 2012;157:120–34.CrossRef
2.
Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–24.CrossRef
3.
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, REDUCE Study Group, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–202.CrossRef
4.
Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:1103–11.CrossRef
5.
Alfaqih MA, Allott EH, Hamilton RJ, Freeman MR, Freedland SJ. The current evidence on statin use and prostate cancer prevention: are we there yet? Nat Rev Urol. 2017;14:107–19.CrossRef
6.
Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst. 2008;100:1511–8.CrossRef
7.
Chang SL, Harshman LC, Presti JC. Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol. 2010;28:3951–7.CrossRef
8.
Bansal D, Undela K, D’Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS ONE. 2012;7:e46691.CrossRef
9.
Tan P, Wei S, Tang Z, Gao L, Zhang C, Nie P, et al. LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies. Sci Rep. 2016;6:24521.CrossRef
10.
Raval AD, Thakker D, Negi H, Vyas A, Salkini MW. Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2016;19:151–62.CrossRef
11.
Babcook MA, Joshi A, Montellano JA, Shankar E, Gupta S. Statin use in prostate cancer: an update. Nutr Metab Insights. 2016;9:43–50.CrossRef
12.
Murtola TJ, Peltomaa AI, Talala K, Määttänen L, Taari K, Tammela TLJ, et al. Statin Use and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer. Eur Urol Focus. 2016. http://​linkinghub.​elsevier.​com/​retrieve/​pii/​S240545691630052​9
13.
Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, et al. Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. JAMA Oncol. 2015;1:495–504.CrossRef
14.
Hamilton RJ, Ding K, Crook JM, O’Callaghan CJ, Higano CS, Dearnaley D, et al. The association between statin use and outcomes in patients initiating androgen deprivation therapy. J Clin Oncol. 2015;33:145–145.CrossRef
15.
Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 2017;541:359–64.CrossRef
16.
Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 2015;47:736–45.CrossRef
17.
Keskiväli T, Kujala P, Visakorpi T, Tammela TLJ, Murtola TJ. Statin use and risk of disease recurrence and death after radical prostatectomy. Prostate. 2016;76:469–78.CrossRef
18.
Vainio P, Lehtinen L, Mirtti T, Hilvo M, Seppänen-Laakso T, Virtanen J, et al. Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget. 2011;2:1176–90.CrossRef
19.
Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2009;18:2807–13.CrossRef
20.
Schnoeller TJ, Jentzmik F, Schrader AJ, Steinestel J, Schnoeller TJ, Jentzmik F, et al. Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness. Oncotarget. 2017;5. http://​www.​oncotarget.​com/​abstract/​16943
21.
Bhindi B, Kulkarni GS, Finelli A, Alibhai SMH, Hamilton RJ, Toi A, et al. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly. Eur Urol. 2014;66:841–8.CrossRef
22.
Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. Cohort. Cancer Epidemiol Biomarkers Prev. 2007;16:2213–7.CrossRef
23.
Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol. 2008;168:250–60.CrossRef
24.
Finelli A, Trottier G, Lawrentschuk N, Sowerby R, Zlotta AR, Radomski L, et al. Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol. 2011;59:509–14.CrossRef
25.
Liu Y, Chen J-Q, Xie L, Wang J, Li T, He Y, et al. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med. 2014;12:55.CrossRef
26.
Agarwal G, Spuches J, Luchey A, Patel T, Pow-Sang J. The effect of NSAID use on disease progression in patients on active surveillance for prostate cancer. J Urol. 2015;193:e756–7.CrossRef
27.
Olivan M, Rigau M, Colás E, Garcia M, Montes M, Sequeiros T, et al. Simultaneous treatment with statins and aspirin reduces the risk of prostate cancer detection and tumorigenic properties in prostate cancer cell lines. Biomed Res Int. 2015;2015:1–11.CrossRef
28.
Fleshner N. Combination statin, acetylsalicylic acid and dutasteride use in prostate cancer. https://​clinicaltrials.​gov/​ct2/​show/​NCT01428869 accessed: 2017 July Year.
29.
Coogan PF, Kelly JP, Strom BL, Rosenberg L. Statin and NSAID use and prostate cancer risk. Pharmacoepidemiol Drug Saf. 2010;19:752–5.CrossRef
30.
Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R, et al. Statin use and risk of prostate cancer in the California Men’s Health Study Cohort. Cancer Epidemiol Biomarkers Prev. 2007;16:2218–25.CrossRef
31.
Hamilton R, Vijai J, Gallagher D, Savage C, Bhatia J, Gaudet M, et al. Analysis of statin medication, genetic variation and prostate cancer outcomes. J Urol. 2011;185:e401.CrossRef
32.
Postmus I, Verschuren JJW, de Craen AJM, Slagboom PE, Westendorp RGJ, Jukema JW, Trompet S. Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives. Pharmacogenomics. 2012;13:831–40.CrossRef
33.
Sun Q, Arnold RS, Sun CQ, Petros JA. A mitochondrial DNA mutation influences the apoptotic effect of statins on prostate cancer. Prostate. 2015;75:1916–25.CrossRef